The National Institute for Health and Care Excellence (NICE) of the UK has issued positive guidance for Janssen Pharmaceutical’s Tremfya (guselkumab) to treat adults suffering from moderate to severe plaque psoriasis.

This positive Health Technology Assessment will provide patients with access to the drug through the National Health Service (NHS) in England and Wales.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Guselkumab is a subcutaneously injectable biologic that selectively targets the interleukin (IL)-23 protein known to trigger an immune inflammatory response in psoriasis. The drug can be used for effective and sustained control of the condition.

As well as NICE’s decision, guselkumab has also secured positive opinion from Germany’s Federal Joint Committee (G-BA), which said that the drug comparatively demonstrated substantial additional therapeutic benefits.

Europe, the Middle East and Africa Janssen Immunology medical lead Jaime Oliver said: “The swift decision by two of Europe’s key Health Technology Assessment bodies reflects the positive results demonstrated in clinical studies of guselkumab for the treatment of moderate to severe plaque psoriasis.

“The swift decision by two of Europe’s key Health Technology Assessment bodies reflects the positive results demonstrated in clinical studies of guselkumab.”

“We are therefore working hard to ensure that eligible patients in Europe can access guselkumab as quickly as possible.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Both positive opinions for guselkumab are based on findings from Phase III clinical studies, including the VOYAGE 1 and 2 trials which evaluated guselkumab in comparison with placebo and Humira (adalimumab) in a total of 837 and 992 subjects, respectively.

Data revealed consistent rates of skin clearance in patients treated with guselkumab for up to two years.

The drug gained European Commission’s marketing authorisation in November last year, and is currently undergoing further investigations in various countries in the European Union.